BofA analyst Michael Cherny raised the firm’s price target on McKesson to $485 from $470 and keeps a Buy rating on the shares. The firm expects “a lot of positive group vibes” from the drug distributor group for upcoming quarter, the analyst tells investors in an earnings preview note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MCK: